Incyte/Novartis's Jakafi/Jakavi stumbles in new polycythemia vera study
This article was originally published in Scrip
Executive Summary
Incyte/Novartis's JAK 1 and 2 kinase inhibitor Jakafi/Jakavi (ruxolitinib) has failed in a Phase III trial in the additional indication of polycythemia vera, but the setback is not expected to affect regulatory plans, Incyte says.